Clearside Biomedical Statistics
Total Valuation
CLSD has a market cap or net worth of $59.84 million. The enterprise value is $100.27 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLSD has 77.71 million shares outstanding. The number of shares has increased by 18.12% in one year.
| Current Share Class | 77.71M |
| Shares Outstanding | 77.71M |
| Shares Change (YoY) | +18.12% |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | 13.26% |
| Owned by Institutions (%) | 14.26% |
| Float | 67.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.46 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.19
| Current Ratio | 3.19 |
| Quick Ratio | 3.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -54.08% |
| Return on Invested Capital (ROIC) | -102.14% |
| Return on Capital Employed (ROCE) | -176.57% |
| Revenue Per Employee | $117,625 |
| Profits Per Employee | -$962,875 |
| Employee Count | 32 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLSD has paid $715,000 in taxes.
| Income Tax | 715,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.36% in the last 52 weeks. The beta is 2.06, so CLSD's price volatility has been higher than the market average.
| Beta (5Y) | 2.06 |
| 52-Week Price Change | -36.36% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 41.70 |
| Average Volume (20 Days) | 419,889 |
Short Selling Information
The latest short interest is 348,964, so 0.45% of the outstanding shares have been sold short.
| Short Interest | 348,964 |
| Short Previous Month | 124,168 |
| Short % of Shares Out | 0.45% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 0.92 |
Income Statement
In the last 12 months, CLSD had revenue of $3.76 million and -$30.81 million in losses. Loss per share was -$0.41.
| Revenue | 3.76M |
| Gross Profit | 3.37M |
| Operating Income | -25.88M |
| Pretax Income | -34.97M |
| Net Income | -30.81M |
| EBITDA | -25.60M |
| EBIT | -25.88M |
| Loss Per Share | -$0.41 |
Full Income StatementBalance Sheet
The company has $13.63 million in cash and $54.06 million in debt, giving a net cash position of -$40.43 million or -$0.52 per share.
| Cash & Cash Equivalents | 13.63M |
| Total Debt | 54.06M |
| Net Cash | -40.43M |
| Net Cash Per Share | -$0.52 |
| Equity (Book Value) | -45.91M |
| Book Value Per Share | -0.59 |
| Working Capital | 10.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.68 million and capital expenditures -$929,000, giving a free cash flow of -$23.61 million.
| Operating Cash Flow | -22.68M |
| Capital Expenditures | -929,000 |
| Free Cash Flow | -23.61M |
| FCF Per Share | -$0.30 |
Full Cash Flow StatementMargins
| Gross Margin | 89.45% |
| Operating Margin | -687.51% |
| Pretax Margin | -799.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLSD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.12% |
| Shareholder Yield | -18.12% |
| Earnings Yield | -51.49% |
| FCF Yield | -39.45% |
Analyst Forecast
The average price target for CLSD is $4.80, which is 523.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.80 |
| Price Target Difference | 523.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 144.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CLSD has an Altman Z-Score of -28.59 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -28.59 |
| Piotroski F-Score | 1 |